 |
BioWorld-International-2008-09-10
UK's Cellzome in $1.5B Deal with GSK for Kinase Inhibitors
Hybrigenics Gets €1.4M for Inecalcitol in Prostate Cancer
No Abstract
PARIS - Hybrigenics SA has been granted a refundable subsidy of €1.4 million (US$2 million) by France's state agency for promoting innovation and supporting small and medium-sized enterprises, OSEO, to finance the development of inecalcitol as a treatment for prostate cancer.
UK's Cellzome in $1.5B Deal with GSK for Kinase Inhibitors
LONDON - Anglo/German kinase specialist Cellzome Inc., sealed a deal worth a headline value of £830 million (US$1.5 billion) with GlaxoSmithKline plc for the development of kinase inhibitors in the treatment of inflammatory diseases. (BioWorld International)